- Home
- ACV vs INMB Comparison
ACV vs INMB Comparison
Compare ACV & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACV
- INMB
- Stock Information
- Founded
- ACV 2015
- INMB 2015
- Country
- ACV United States
- INMB United States
- Employees
- ACV N/A
- INMB N/A
- Industry
- ACV Finance/Investors Services
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- ACV Finance
- INMB Health Care
- Exchange
- ACV Nasdaq
- INMB Nasdaq
- Market Cap
- ACV 197.6M
- INMB 176.5M
- IPO Year
- ACV N/A
- INMB 2019
- Fundamental
- Price
- ACV $21.16
- INMB $6.97
- Analyst Decision
- ACV
- INMB Strong Buy
- Analyst Count
- ACV 0
- INMB 3
- Target Price
- ACV N/A
- INMB $24.33
- AVG Volume (30 Days)
- ACV 38.8K
- INMB 215.6K
- Earning Date
- ACV 01-01-0001
- INMB 05-08-2025
- Dividend Yield
- ACV 9.20%
- INMB N/A
- EPS Growth
- ACV N/A
- INMB N/A
- EPS
- ACV N/A
- INMB N/A
- Revenue
- ACV N/A
- INMB $50,000.00
- Revenue This Year
- ACV N/A
- INMB N/A
- Revenue Next Year
- ACV N/A
- INMB N/A
- P/E Ratio
- ACV N/A
- INMB N/A
- Revenue Growth
- ACV N/A
- INMB N/A
- 52 Week Low
- ACV $16.82
- INMB $4.32
- 52 Week High
- ACV $23.74
- INMB $11.76
- Technical
- Relative Strength Index (RSI)
- ACV 65.77
- INMB 40.42
- Support Level
- ACV $20.25
- INMB $6.98
- Resistance Level
- ACV $20.58
- INMB $8.00
- Average True Range (ATR)
- ACV 0.38
- INMB 0.49
- MACD
- ACV 0.19
- INMB -0.07
- Stochastic Oscillator
- ACV 89.79
- INMB 6.59
About ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.